Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。

サイズ 価格 在庫  
USD 114 あり
USD 88 あり
USD 340 あり

カスタマーフィードバック(3)

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzTTWM2OD1yLkCwNFI5PyEQvF2= NUT1d4dxW0GQR1XS
LC-2-ad MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMECwN|E4KM7:TR?= NFHGVIFUSU6JRWK=
RL95-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PSdGlEPTB;MD6wNFA3PjhizszN MlvoV2FPT0WU
MZ1-PC MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXVeoFEUUN3ME2wMlAxODd{OTFOwG0> MWTTRW5ITVJ?
TE-8 M1OyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\xRmlEPTB;MD6wNFEyPyEQvF2= NVLJWWtYW0GQR1XS
SW954 NVL6cJd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULUTJlxUUN3ME2wMlAxOTF7IN88US=> NGnkRlhUSU6JRWK=
TE-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfRSmJKSzVyPUCuNFAyOjNizszN NGXWPGhUSU6JRWK=
PSN1 NH3tNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHGOYtKSzVyPUCuNFAyOyEQvF2= NFzLd4lUSU6JRWK=
MOLT-4 NFn4O|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnvV2REUUN3ME2wMlAxOTR7IN88US=> MWLTRW5ITVJ?
697 M17LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzZ5Z[UUN3ME2wMlAxOTVizszN MX3TRW5ITVJ?
ETK-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxcWlEPTB;MD6wNFE2OiEQvF2= NF7XWlJUSU6JRWK=
TE-10 NYHYc|BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLVXVNKSzVyPUCuNFAyPTRizszN M4PPSXNCVkeHUh?=
HUTU-80 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLvUnhwUUN3ME2wMlAxOTZ6IN88US=> M1m0O3NCVkeHUh?=
NTERA-S-cl-D1 M3fWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj5TWM2OD1yLkCwNlA6KM7:TR?= MVrTRW5ITVJ?
MFH-ino NImxVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMECyOlgh|ryP NYXxdGlkW0GQR1XS
IA-LM M1TvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zwbGlEPTB;MD6wNFI5KM7:TR?= NGTWZ4NUSU6JRWK=
MC116 NFe0TY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzIOYxRUUN3ME2wMlAxOjh7IN88US=> NEPyOHlUSU6JRWK=
RKO NH7yZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHpdYNvUUN3ME2wMlAxOjl6IN88US=> MlOwV2FPT0WU
MRK-nu-1 NHThRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjG[3JKSzVyPUCuNFAzQTlizszN MWTTRW5ITVJ?
VA-ES-BJ Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3xN21KSzVyPUCuNFA{KM7:TR?= M37k[HNCVkeHUh?=
KALS-1 NFfnSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTuTWM2OD1yLkCwN|A5KM7:TR?= MUjTRW5ITVJ?
BB30-HNC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMECzNVQh|ryP M2TzRXNCVkeHUh?=
ACN MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKyeWpKSzVyPUCuNFA{OTZizszN M1y4SXNCVkeHUh?=
TE-9 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfwc3RWUUN3ME2wMlAxOzJ4IN88US=> MUPTRW5ITVJ?
SIG-M5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF30b3RKSzVyPUCuNFA{OjdizszN NFXTPW5USU6JRWK=
no-10 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMECzOlIh|ryP NXXOdlhlW0GQR1XS
EW-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\zZmlEPTB;MD6wNFM4OSEQvF2= M37SWXNCVkeHUh?=
SK-LMS-1 M1\2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rqb2lEPTB;MD6wNFQxOSEQvF2= NX\uRnBQW0GQR1XS
GT3TKB NFy4UVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1yLkCwOFM1KM7:TR?= M1rkNnNCVkeHUh?=
ES4 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEC0OFkh|ryP M3;MdHNCVkeHUh?=
IMR-5 M2Tsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TIOWlEPTB;MD6wNFQ2KM7:TR?= M2L4PHNCVkeHUh?=
NCI-H1648 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fuRWlEPTB;MD6wNFQ3QSEQvF2= MX7TRW5ITVJ?
MV-4-11 M13RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOzTWM2OD1yLkCwOFc2KM7:TR?= MULTRW5ITVJ?
SK-UT-1 M2XjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;wZW1KSzVyPUCuNFA1QCEQvF2= NF;pTnpUSU6JRWK=
NB13 NVfnT3pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjVmFyUUN3ME2wMlAxPDlzIN88US=> MXLTRW5ITVJ?
DJM-1 M175N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomwTWM2OD1yLkCwOVMh|ryP NXrJWHFCW0GQR1XS
ES8 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC1N|gh|ryP M1fSXnNCVkeHUh?=
TE-6 NXvjdHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\RSHZKSzVyPUCuNFA2PyEQvF2= M{noSXNCVkeHUh?=
KS-1 NIDlOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEC1PFIh|ryP M{jNOHNCVkeHUh?=
TE-1 M4fCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPDTWM2OD1yLkCwOlA3KM7:TR?= Mn[wV2FPT0WU
ATN-1 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDYbZFKSzVyPUCuNFA3ODlizszN Mk\aV2FPT0WU
A4-Fuk NWnKdZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\OTWM2OD1yLkCwOlEyKM7:TR?= MXXTRW5ITVJ?
ALL-PO MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPZTWM2OD1yLkCwOlMh|ryP MVfTRW5ITVJ?
BE-13 NFvR[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEC2N|Yh|ryP NWnWdHFzW0GQR1XS
KM12 M{XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEC2N|ch|ryP NV3Qe3VqW0GQR1XS
NOS-1 NY\aPJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS5TWM2OD1yLkCwOlUh|ryP Mm\SV2FPT0WU
SW962 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnTWM2OD1yLkCwOlYzKM7:TR?= MUTTRW5ITVJ?
OCUB-M MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqWZdDUUN3ME2wMlAxPjZ{IN88US=> MVjTRW5ITVJ?
NCI-H510A NIfrWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TmeGlEPTB;MD6wNFY3PSEQvF2= M3vYVHNCVkeHUh?=
EW-16 NEWzNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ZV2lEPTB;MD6wNFY6PCEQvF2= M2f5WHNCVkeHUh?=
KGN NUPDOZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrxTWM2OD1yLkCwO|EzKM7:TR?= NVf6NFJvW0GQR1XS
LS-411N NFXibG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD1yLkCwO|E4KM7:TR?= NHPEOHVUSU6JRWK=
Becker M3jJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjvWWhJUUN3ME2wMlAxPzJizszN M2X6VXNCVkeHUh?=
HC-1 M4H0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvPTWM2OD1yLkCwO|IyKM7:TR?= NHWxVHdUSU6JRWK=
CESS NWLBRoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pjd2lEPTB;MD6wNFc{PyEQvF2= M2nWSHNCVkeHUh?=
KURAMOCHI NUHoTIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEC3OFgh|ryP M{LBcHNCVkeHUh?=
TGBC24TKB M4m5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfwUHZKSzVyPUCuNFA4PTJizszN NHmzRppUSU6JRWK=
SW982 NUfMTodsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[zSXJKSzVyPUCuNFA4PjZizszN M{fPd3NCVkeHUh?=
HCE-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1yLkCwO|Y4KM7:TR?= MUHTRW5ITVJ?
LOUCY MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDPdXN7UUN3ME2wMlAxPzd3IN88US=> M3TKRXNCVkeHUh?=
8-MG-BA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXOTWM2OD1yLkCwO|k3KM7:TR?= M1Xh[XNCVkeHUh?=
HT-144 NXzX[Gp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPoU|htUUN3ME2wMlAxQCEQvF2= NInLNmVUSU6JRWK=
LXF-289 M4nqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DaW2lEPTB;MD6wNFgyQCEQvF2= MlH1V2FPT0WU
RS4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEC4N|Yh|ryP MV;TRW5ITVJ?
DEL M4\uOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEC4OFUh|ryP M4HLNnNCVkeHUh?=
OCI-AML2 M3;0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzVTWM2OD1yLkCwPFUzKM7:TR?= NFq1VWpUSU6JRWK=
CCRF-CEM NXnydlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPoTY06UUN3ME2wMlAxQDdzIN88US=> M1vFZnNCVkeHUh?=
A388 NFrTdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPabpZKSzVyPUCuNFA5PzRizszN MXTTRW5ITVJ?
KNS-42 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEC4PVEh|ryP MoC3V2FPT0WU
OVCAR-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rQNGlEPTB;MD6wNFkxPCEQvF2= M3:2c3NCVkeHUh?=
NCI-H1355 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEC5NVQh|ryP M120RXNCVkeHUh?=
BL-70 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vIZWlEPTB;MD6wNFk{KM7:TR?= MY\TRW5ITVJ?
BL-41 NYPnfHVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\pTWM2OD1yLkCwPVM1KM7:TR?= MVLTRW5ITVJ?
A101D MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEC5OkDPxE1? NYrKRW1NW0GQR1XS
HL-60 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i4OmlEPTB;MD6wNFk3PiEQvF2= MV\TRW5ITVJ?
COR-L279 NFvoRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDwTWM2OD1yLkCwPVk6KM7:TR?= MV\TRW5ITVJ?
NCI-SNU-16 NF3KOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnmZYd6UUN3ME2wMlAyODB6IN88US=> M1fw[3NCVkeHUh?=
Calu-6 M4rlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;5PGlEPTB;MD6wNVAyOiEQvF2= NWPEZmVrW0GQR1XS
SR NFjheI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zmPWlEPTB;MD6wNVAzPiEQvF2= MVvTRW5ITVJ?
QIMR-WIL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLMTWM2OD1yLkCxNFM{KM7:TR?= NV6xcG15W0GQR1XS
LB647-SCLC MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3ZXnlKSzVyPUCuNFExPTFizszN M3TOT3NCVkeHUh?=
RPMI-8226 NXjyXYFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S0[WlEPTB;MD6wNVExOiEQvF2= NFXCSHRUSU6JRWK=
SK-PN-DW NI[5TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vleGlEPTB;MD6wNVEyOiEQvF2= MWHTRW5ITVJ?
SF268 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrBfIh4UUN3ME2wMlAyOTVzIN88US=> MXLTRW5ITVJ?
HD-MY-Z MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrXbZdKSzVyPUCuNFEyPjNizszN MV7TRW5ITVJ?
DOHH-2 NHjCe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMEGyNFMh|ryP M2jPXHNCVkeHUh?=
SCC-3 NXXVZY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vvZmlEPTB;MD6wNVIxPCEQvF2= MnG2V2FPT0WU
ST486 M2KwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXWSpdKSzVyPUCuNFEzODRizszN M4nEOnNCVkeHUh?=
NALM-6 M3fyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDYTWM2OD1yLkCxNlE1KM7:TR?= NEm0ZYlUSU6JRWK=
NCI-H1436 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37DbmlEPTB;MD6wNVI{OSEQvF2= NF3VfFJUSU6JRWK=
KE-37 NUPkc2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEGyN|Qh|ryP NEj1T2tUSU6JRWK=
RPMI-8402 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fwXGlEPTB;MD6wNVI2PiEQvF2= MUjTRW5ITVJ?
RXF393 NXnCcJlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf0dYxKSzVyPUCuNFEzPTdizszN NY\TbG8{W0GQR1XS
KARPAS-45 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEGyO{DPxE1? MVTTRW5ITVJ?
HOP-62 NHTUOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHqZ3lKSzVyPUCuNFEzPzZizszN MV7TRW5ITVJ?
ES1 NHqzWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEGyPFgh|ryP NFfz[mlUSU6JRWK=
L-363 NG\aW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy5NpFZUUN3ME2wMlAyOzVzIN88US=> Mk\4V2FPT0WU
GI-1 NEKxXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LQPWlEPTB;MD6wNVM4OyEQvF2= NIH4[pZUSU6JRWK=
CTV-1 M1[wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEG0O|gh|ryP NFnwdFNUSU6JRWK=
TE-5 M2W5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofBTWM2OD1yLkCxOFk3KM7:TR?= MmrLV2FPT0WU
SNU-C2B NIjpXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0ZmlEPTB;MD6wNVQ6PiEQvF2= Mlj0V2FPT0WU
K-562 NIrmVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHTTWM2OD1yLkCxOVE3KM7:TR?= Mof3V2FPT0WU
SNB75 NUP2dXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni2TWM2OD1yLkCxOVQh|ryP NGTTV5pUSU6JRWK=
MOLT-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEG2N|ch|ryP NXT5do9CW0GQR1XS
LS-123 NILmeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC5TW1oUUN3ME2wMlAyPjZ2IN88US=> MV7TRW5ITVJ?
NCI-SNU-5 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTG[It6UUN3ME2wMlAyPzBzIN88US=> MWTTRW5ITVJ?
Daudi Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEG3NFgh|ryP MXPTRW5ITVJ?
A253 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEG3N|gh|ryP MYjTRW5ITVJ?
TGBC1TKB NFf2XZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP4dlRKSzVyPUCuNFE4PTJizszN NUDNTZY1W0GQR1XS
SJSA-1 NF3CU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXqZ5lYUUN3ME2wMlAyPzZ5IN88US=> NH3kT|JUSU6JRWK=
NCCIT MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK2bWdTUUN3ME2wMlAyPzZ7IN88US=> M{\lPHNCVkeHUh?=
NCI-H69 NH:yclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\CSI1KSzVyPUCuNFE4PzhizszN MYDTRW5ITVJ?
SH-4 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD1yLkCxPFk2KM7:TR?= M3TLbXNCVkeHUh?=
HCC1187 M1\l[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3id3dKSzVyPUCuNFE6OjRizszN NEfqcYZUSU6JRWK=
HCC1599 NW\5b2p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHjeIVEUUN3ME2wMlAzODJizszN Moq4V2FPT0WU
ONS-76 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ixS2lEPTB;MD6wNlA{PiEQvF2= NH7KSI5USU6JRWK=
KU812 NVy1dpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXwOpB4UUN3ME2wMlAzODN7IN88US=> NGHKcmtUSU6JRWK=
ML-2 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEKwOFch|ryP NUL4RWNNW0GQR1XS
HCE-T M{L0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zwRmlEPTB;MD6wNlA6OiEQvF2= MUfTRW5ITVJ?
NCI-H446 M3GyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HRUGlEPTB;MD6wNlEyOiEQvF2= NXu0T5dkW0GQR1XS
RPMI-6666 NUWxXlFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f1OGlEPTB;MD6wNlE1QSEQvF2= MnjmV2FPT0WU
MOLT-16 M{\Fcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfVT2dKSzVyPUCuNFIyPTNizszN M2XUVHNCVkeHUh?=
JiyoyeP-2003 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEKxO|Yh|ryP M3n0ZXNCVkeHUh?=
MHH-PREB-1 NXnrfZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17vZ2lEPTB;MD6wNlE6OSEQvF2= NEPWPZhUSU6JRWK=
MC-CAR NYPLSZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:0TZJKSzVyPUCuNFI{OjZizszN NFLWUo5USU6JRWK=
BC-3 NYHPeJJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLjTWM2OD1yLkCyN|Q1KM7:TR?= M{XFPXNCVkeHUh?=
KINGS-1 NH;tVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEKzOVUh|ryP M1PVNXNCVkeHUh?=
PF-382 M3vzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEKzO|gh|ryP NE[4U5ZUSU6JRWK=
J-RT3-T3-5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LkdWlEPTB;MD6wNlM5OyEQvF2= MlvUV2FPT0WU
SF539 M{TUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzzdZZCUUN3ME2wMlAzPDBzIN88US=> NFfyeJdUSU6JRWK=
LB831-BLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEK0PFUh|ryP MlPPV2FPT0WU
DMS-114 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmRmlEPTB;MD6wNlUxOiEQvF2= NXrqb4VDW0GQR1XS
LB1047-RCC NXj1foNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEK1NUDPxE1? MkPVV2FPT0WU
LB771-HNC M1u0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DZVGlEPTB;MD6wNlU{PCEQvF2= NIXSR3VUSU6JRWK=
BB65-RCC NG[5VnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD1yLkCyOVM1KM7:TR?= NYH6TZd[W0GQR1XS
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEK1OVQh|ryP MXnTRW5ITVJ?
ARH-77 NWrGeYF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP6TIYzUUN3ME2wMlAzPjBzIN88US=> NX7hOI5uW0GQR1XS
IST-MEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DKVWlEPTB;MD6wNlYzOyEQvF2= NYq5[mJyW0GQR1XS
NB1 NW\u[mJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH3OWpKSzVyPUCuNFI3QDdizszN NGXy[W5USU6JRWK=
EoL-1-cell NEXtVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC0bWk4UUN3ME2wMlAzPjh6IN88US=> MXfTRW5ITVJ?
KY821 NFPMfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEK2PVch|ryP NETpW3hUSU6JRWK=
CMK MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEK3N|Qh|ryP NH3hdHlUSU6JRWK=
NCI-H2126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1dohKSzVyPUCuNFI4PjhizszN NHrwOIZUSU6JRWK=
NCI-H526 M1r3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyyb|JyUUN3ME2wMlAzQDlzIN88US=> MYHTRW5ITVJ?
COLO-684 NIPXfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofWTWM2OD1yLkCyPVA5KM7:TR?= M4DlVnNCVkeHUh?=
NCI-H747 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HyWGlEPTB;MD6wNlk{OyEQvF2= NHnsfIFUSU6JRWK=
JAR NGjQfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTzTWM2OD1yLkCyPVQ3KM7:TR?= MlTYV2FPT0WU
MEG-01 NICyOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nmNGlEPTB;MD6wNlk4QCEQvF2= MWHTRW5ITVJ?
MONO-MAC-6 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj3NoZmUUN3ME2wMlA{ODJ|IN88US=> MkT3V2FPT0WU
IST-SL1 NVG3XW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWTmlEPTB;MD6wN|A1OiEQvF2= M16xOXNCVkeHUh?=
CPC-N MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEOwO|kh|ryP M1rEZ3NCVkeHUh?=
NCI-H1963 NUHyOHptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS0TWM2OD1yLkCzNVMyKM7:TR?= MVjTRW5ITVJ?
K052 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEOyOFch|ryP MmrKV2FPT0WU
KM-H2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jhN2lEPTB;MD6wN|MxPyEQvF2= MUPTRW5ITVJ?
TE-12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3sVY5KSzVyPUCuNFM{ODlizszN MYTTRW5ITVJ?
TK10 NHnISWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEOzOVYh|ryP NYjsU2FFW0GQR1XS
NMC-G1 M2e4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG3TWM2OD1yLkCzOFUzKM7:TR?= MUDTRW5ITVJ?
no-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fn[2lEPTB;MD6wN|Q4QCEQvF2= M1TZe3NCVkeHUh?=
NCI-H524 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\yTWM2OD1yLkCzOVI6KM7:TR?= M3GwcHNCVkeHUh?=
MHH-CALL-2 NYK0Z3BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEO1OlIh|ryP MkSzV2FPT0WU
GB-1 NV;RdYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LwXGlEPTB;MD6wN|Yh|ryP M1f5T3NCVkeHUh?=
OPM-2 NGD2[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEO2O|Mh|ryP NWHGfmhxW0GQR1XS
RH-1 M1;jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:yUlk{UUN3ME2wMlA{QDF7IN88US=> Mlq5V2FPT0WU
NCI-H64 NGXqO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjxe3JKSzVyPUCuNFM5PTdizszN MWLTRW5ITVJ?
EVSA-T NWTBTFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEO5NlMh|ryP NWToNJpsW0GQR1XS
KARPAS-299 NI\jVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfQN5RVUUN3ME2wMlA{QThizszN NETnO4tUSU6JRWK=
MZ7-mel MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnlTWM2OD1yLkC0NFQh|ryP MlP3V2FPT0WU
LB373-MEL-D MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGzTWM2OD1yLkC0NVA2KM7:TR?= NGPiWWRUSU6JRWK=
HEL MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMESxOEDPxE1? M2KxNHNCVkeHUh?=
SW872 NYHBbVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknLTWM2OD1yLkC0NlEh|ryP M2LDSXNCVkeHUh?=
DU-4475 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjySotrUUN3ME2wMlA1OjR2IN88US=> M33VTXNCVkeHUh?=
IST-SL2 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjqTZhuUUN3ME2wMlA1Ojd3IN88US=> MmXGV2FPT0WU
NCI-H82 NHyyOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMESzNFch|ryP M2HKTHNCVkeHUh?=
LC4-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMESzOVEh|ryP MmX1V2FPT0WU
HDLM-2 M3vDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj1TWM2OD1yLkC0N|kzKM7:TR?= NH;DZVlUSU6JRWK=
MMAC-SF MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGweGMxUUN3ME2wMlA1PTN2IN88US=> MV\TRW5ITVJ?
L-540 NXT5VJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMES2N|kh|ryP NWXBZ5o4W0GQR1XS
MZ2-MEL M{\hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOwSYVKSzVyPUCuNFQ4PDJizszN MkTIV2FPT0WU
LU-134-A NXO1XWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nKcWlEPTB;MD6wOFc4OyEQvF2= Ml;hV2FPT0WU
UACC-257 M1;Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLJ[WRKSzVyPUCuNFQ5PDlizszN MUjTRW5ITVJ?
NCI-H1581 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TXVmlEPTB;MD6wOFk2OyEQvF2= M2ezTXNCVkeHUh?=
NB17 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnMNnFKSzVyPUCuNFQ6PzlizszN NYTrbJRbW0GQR1XS
SBC-1 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofiTWM2OD1yLkC1NFQzKM7:TR?= MoHGV2FPT0WU
TALL-1 NGHmNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzKTWM2OD1yLkC1NFQ2KM7:TR?= MYTTRW5ITVJ?
NCI-H1304 NVy1d3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEWyNFgh|ryP MkPaV2FPT0WU
NEC8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364WWlEPTB;MD6wOVI5PiEQvF2= M1Lve3NCVkeHUh?=
CAL-148 NF;qSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEW0N|kh|ryP M4DHOXNCVkeHUh?=
CGTH-W-1 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZTWM2OD1yLkC1OFQ6KM7:TR?= NGDWU2pUSU6JRWK=
NCI-H889 NXXMSXR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uTWM2OD1yLkC1OVkzKM7:TR?= NYjhbnJpW0GQR1XS
GR-ST MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTqTWM2OD1yLkC1OlIyKM7:TR?= NVXScIVlW0GQR1XS
KARPAS-422 M3XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nZVWlEPTB;MD6wOVY2KM7:TR?= M1f6bnNCVkeHUh?=
RPMI-8866 NV[zboMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jxXWlEPTB;MD6wOVcyOiEQvF2= MVnTRW5ITVJ?
SCLC-21H NYr4W|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CS2lEPTB;MD6wOVg5PCEQvF2= M3LIOHNCVkeHUh?=
COR-L88 M1HHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3yyfGlEPTB;MD6wOVkzPyEQvF2= MWTTRW5ITVJ?
LU-139 NInzbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPWWlEPTB;MD6wOVk5PiEQvF2= NW\1UJFIW0GQR1XS
SF126 M1n4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfL[mJKSzVyPUCuNFYyOzNizszN MUnTRW5ITVJ?
NCI-H1882 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfuPYdvUUN3ME2wMlA3PDJ2IN88US=> MVrTRW5ITVJ?
EW-24 NWe3R4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r0NmlEPTB;MD6wOlQ5OyEQvF2= Moe4V2FPT0WU
CP67-MEL M3flfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\vbJBKSzVyPUCuNFY5OSEQvF2= Ml\YV2FPT0WU
DG-75 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO0TWM2OD1yLkC2PFk6KM7:TR?= NEP5Zm9USU6JRWK=
LOXIMVI M3nxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\wVWhKSzVyPUCuNFcxOjhizszN MnflV2FPT0WU
HH M3XoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDjbnJ4UUN3ME2wMlA4OTV5IN88US=> MX;TRW5ITVJ?
K5 NEPSWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\5XHloUUN3ME2wMlA4OjJ4IN88US=> MlLXV2FPT0WU
EC-GI-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEeyOVch|ryP MULTRW5ITVJ?
SK-N-DZ NWDacoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX6TWM2OD1yLkC3N|A4KM7:TR?= M323e3NCVkeHUh?=
A3-KAW NGPKPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zOPWlEPTB;MD6wO|M2OSEQvF2= MnfFV2FPT0WU
MLMA Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxVW1KSzVyPUCuNFc1PjVizszN NF\Kc3FUSU6JRWK=
LB996-RCC NVPYdJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXublNtUUN3ME2wMlA4PzB5IN88US=> NFjqcHVUSU6JRWK=
OS-RC-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKSXJKSzVyPUCuNFc4PDhizszN M{jCPXNCVkeHUh?=
CTB-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xNYFvUUN3ME2wMlA4QDFizszN NEL6Z21USU6JRWK=
IST-MES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD1yLkC3PVEzKM7:TR?= MVTTRW5ITVJ?
LS-1034 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jWc2lEPTB;MD6wPFA{PSEQvF2= MlvwV2FPT0WU
HT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tRlFKSzVyPUCuNFgxQDZizszN NIr6O4dUSU6JRWK=
NCI-H2141 M2H6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXpUZJ5UUN3ME2wMlA5OSEQvF2= M4HvenNCVkeHUh?=
LB2518-MEL NH3KUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPVTWM2OD1yLkC4NVQyKM7:TR?= Mki3V2FPT0WU
GI-ME-N M13jU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK4TWM2OD1yLkC4OFUzKM7:TR?= MWnTRW5ITVJ?
TGW M4nPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEi2NFch|ryP MULTRW5ITVJ?
SK-NEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r5RmlEPTB;MD6wPFY1OSEQvF2= NUfsfY51W0GQR1XS
NOMO-1 NEHTdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEmyO|Uh|ryP MVnTRW5ITVJ?
ES6 NHjGWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnIVFJKSzVyPUCuNFk2QDlizszN MlP3V2FPT0WU
NCI-H209 M3Gy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEm3PFYh|ryP NV7kN2VXW0GQR1XS
GAK NHvGU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMUCxOkDPxE1? MYnTRW5ITVJ?
BC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7FTWM2OD1yLkGwN|YyKM7:TR?= NWfvNnNOW0GQR1XS
KLE M{Hrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSwTWM2OD1yLkGwOFQ{KM7:TR?= MljIV2FPT0WU
EW-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHpTWM2OD1yLkGwPVgh|ryP NFe5bVhUSU6JRWK=
NKM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILYTZlKSzVyPUCuNVEyKM7:TR?= M3jZOHNCVkeHUh?=
D-336MG M2TaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMUGyOFQh|ryP MoPzV2FPT0WU
NB69 M4nwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUGzNFEh|ryP M1joNnNCVkeHUh?=
D-263MG M2G5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfGbJlKSzVyPUCuNVE4OTJizszN MYDTRW5ITVJ?
KP-N-YS NI[3VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v4cGlEPTB;MD6xNlI6OSEQvF2= NXHrc2dEW0GQR1XS
NCI-H1155 M37oNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHlT5ZKSzVyPUCuNVI2PThizszN M33mdnNCVkeHUh?=
BOKU MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDWTWM2OD1yLkGyOVc6KM7:TR?= M1fVTnNCVkeHUh?=
LAMA-84 NXLhN3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXTb5pKSzVyPUCuNVI6QSEQvF2= M4\zS3NCVkeHUh?=
Raji M2ThRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXqTodlUUN3ME2wMlE{OTF5IN88US=> NYrSO2VpW0GQR1XS
LU-65 M3rTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDQW3JxUUN3ME2wMlE{OzB5IN88US=> MoPtV2FPT0WU
NCI-H187 NH;ZXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUO5NlQh|ryP M1vwdXNCVkeHUh?=
GCIY NGHBSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;3WGhMUUN3ME2wMlE1QTBzIN88US=> M{OzVHNCVkeHUh?=
NCI-H2107 NYrxSG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMUWwPEDPxE1? MWTTRW5ITVJ?
NCI-H1522 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\kTWM2OD1yLkG1NlY3KM7:TR?= M3;jeXNCVkeHUh?=
NB6 NWn1W2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHsNYxKSzVyPUCuNVU3OjNizszN M1T3THNCVkeHUh?=
EM-2 NEPrOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7lOm1KSzVyPUCuNVU4ODZizszN Mn\qV2FPT0WU
HCC2218 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPEOXJKSzVyPUCuNVU6QCEQvF2= M3X4bXNCVkeHUh?=
NCI-H748 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMU[zO|Yh|ryP NFPY[3lUSU6JRWK=
MS-1 NVrhXJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\YRoZmUUN3ME2wMlE3PTN5IN88US=> MnnGV2FPT0WU
NB5 NH\vZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\qe4h[UUN3ME2wMlE3PTl5IN88US=> NIfHbmlUSU6JRWK=
OMC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMU[2PFgh|ryP MUTTRW5ITVJ?
NCI-H345 M3q4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEewUJBKSzVyPUCuNVY6OjhizszN MlrUV2FPT0WU
L-428 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLMU3pKSzVyPUCuNVY6PDVizszN M1XXPXNCVkeHUh?=
SCH M4rXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLNSYNWUUN3ME2wMlE5Pjh3IN88US=> M1PjNnNCVkeHUh?=
NCI-H1417 M3XNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvYVIV[UUN3ME2wMlE6OjJ5IN88US=> MlTQV2FPT0WU
COLO-320-HSR NFHlSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LlRWlEPTB;MD6xPVU{OiEQvF2= MYDTRW5ITVJ?
BT-474 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHyfYRHUUN3ME2wMlIxQDl{IN88US=> MUTTRW5ITVJ?
GDM-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fKXmlEPTB;MD6yNVk4OSEQvF2= NF7nSIRUSU6JRWK=
NCI-H2196 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvTd4Y{UUN3ME2wMlIzOjN3IN88US=> NEnkT5hUSU6JRWK=
KP-N-RT-BM-1 NHzVeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkTWM2OD1yLkKyN|Q6KM7:TR?= NY\1TmJnW0GQR1XS
KNS-81-FD NEfGR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\uRnZKSzVyPUCuNlI6PThizszN NGntenBUSU6JRWK=
COLO-668 M3jDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMkO2O|Uh|ryP NX23XJVpW0GQR1XS
C2BBe1 NXzncoNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\IV5RMUUN3ME2wMlI3PzR5IN88US=> M1XlcHNCVkeHUh?=
Ramos-2G6-4C10 M3[0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMk[5OVQh|ryP MWDTRW5ITVJ?
CAS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMkewPVYh|ryP NYT6N5cxW0GQR1XS
GOTO NV7TPYhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjMNlVIUUN3ME2wMlI4QDl2IN88US=> MoT3V2FPT0WU
LP-1 NXXtR25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Yd4RKSzVyPUCuNlgxPTdizszN NIG1RnJUSU6JRWK=
NCI-SNU-1 M{LpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMkm0NlIh|ryP MVXTRW5ITVJ?
EB-3 NIjQTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK4XY1KSzVyPUCuNlk6PzlizszN MYTTRW5ITVJ?
MHH-NB-11 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv6co1KSzVyPUCuN|A1ODJizszN NXr1SZJWW0GQR1XS
SK-N-FI NGWx[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLpWZRvUUN3ME2wMlMyPjl{IN88US=> NGSwZVlUSU6JRWK=
HCC2157 NYXteHoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL4TWM2OD1yLkOzPVE{KM7:TR?= NH;M[FJUSU6JRWK=
SIMA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTBcFB6UUN3ME2wMlM1PThzIN88US=> MlTBV2FPT0WU
MDA-MB-134-VI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml74TWM2OD1yLkO2PVI5KM7:TR?= MXzTRW5ITVJ?
NCI-H1694 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Kd40xUUN3ME2wMlM4KM7:TR?= NFT3eFlUSU6JRWK=
EHEB M1zaXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml24TWM2OD1yLkO5NFg2KM7:TR?= MmDyV2FPT0WU
U-266 NGPZOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXrVFlXUUN3ME2wMlM6QDR4IN88US=> M2nEVHNCVkeHUh?=
LC-1F M3vPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnLbHhKSzVyPUCuOFM4PjVizszN MUXTRW5ITVJ?
SHP-77 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELFfXNKSzVyPUCuOFc5PTVizszN M{DhcnNCVkeHUh?=
LS-513 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPmTWM2OD1yLkS5N|A4KM7:TR?= NXHablFTW0GQR1XS

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water slightly soluble or insoluble
体内 順序で溶剤を入れること:
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
in solvent
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 問題2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID